Literature DB >> 14996742

Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose.

Yuichi Nakajima1, Takenari Gotanda, Hiroshi Uchimiya, Tatsuhiko Furukawa, Misako Haraguchi, Ryuji Ikeda, Tomoyuki Sumizawa, Hiroki Yoshida, Shin-Ichi Akiyama.   

Abstract

Thymidine phosphorylase (TP) catalyzes the reversible conversion of thymidine to thymine, thereby generating 2-deoxy-D-ribose-1-phosphate, which upon dephosphorylation forms 2-deoxy-D-ribose (D-dRib), a degradation product of thymidine. We have previously shown that D-dRib promotes angiogenesis and chemotaxis of endothelial cells and also confers resistance to hypoxia-induced apoptosis in some cancer cell lines. 2-Deoxy-L-ribose (L-dRib), a stereoisomer of D-dRib, can inhibit D-dRib anti-apoptotic effects and suppressed the growth of KB cells overexpressing TP (KB/TP cells) transplanted into nude mice. In this study, we examined the ability of L-dRib to suppress metastasis of KB/TP cells using two different models of metastasis. The antimetastatic effect of L-dRib was first investigated in a liver-metastasis model in nude mice inoculated with KB/TP cells. Oral administration of L-dRib for 28 days at a dose of 20 mg/kg/day significantly reduced the number of metastatic nodules in the liver and suppressed angiogenesis and enhanced apoptosis in KB/TP metastatic nodules. Next, we compared the ability of L-dRib and tegafur alone or in combination to decrease the number of metastatic nodules in organs in the abdominal cavity in nude mice receiving s.c. of KB/TP cells into their backs. L-dRib (20 mg/kg/day) was significantly (P < 0.05) more efficient than tegafur (100 mg/kg/day) in decreasing the number of metastatic nodules in organs in the abdominal cavity. By in vitro invasion assay, L-dRib also reduced the number of invading KB/TP cells. L-dRib anti-invasive activity may be mediated by its ability to suppress the enhancing effect of TP and D-dRib on both mRNA and protein expression of vascular endothelial growth factor and interleukin-8 in cultured KB cells. These findings suggest that L-dRib may be useful in a clinical setting for the suppression of metastasis of tumor cells expressing TP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996742     DOI: 10.1158/0008-5472.can-03-2597

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.

Authors:  Jongkonnee Thanasai; Temduang Limpaiboon; Patcharee Jearanaikoon; Banchob Sripa; Chawalit Pairojkul; Srisurang Tantimavanich; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

2.  Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma.

Authors:  Jongkonnee Thanasai; Temduang Limpaiboon; Patcharee Jearanaikoon; Vajarabhongsa Bhudhisawasdi; Narong Khuntikeo; Banchob Sripa; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

3.  Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.

Authors:  Haiyan Lu; Robert S Klein; Edward L Schwartz
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

4.  6-Azido-6-de-oxy-α-l-galactose (6-azido-l-fucose) monohydrate.

Authors:  K Victoria Booth; Sarah F Jenkinson; Devendar Rao; Tsuyosi Simonisi; George W J Fleet; Ken Izumori; David J Watkin
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-07-23

5.  Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors.

Authors:  I V Bijnsdorp; F Capriotti; F A E Kruyt; N Losekoot; M Fukushima; A W Griffioen; V L Thijssen; G J Peters
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

6.  Predicting lymph node status in patients with early gastric carcinoma using double contrast-enhanced ultrasonography.

Authors:  Nianyu Xue; Pintong Huang; Wilbert S Aronow; Zongmin Wang; Chandra K Nair; Zhiqiang Zheng; Xuedong Shen; Yimei Yin; Fuguang Huang; David Cosgrove
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

7.  Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.

Authors:  N S Brown; E H Streeter; A Jones; A L Harris; R Bicknell
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

8.  Thymidine phosphorylase activates NFκB and stimulates the expression of angiogenic and metastatic factors in human cancer cells.

Authors:  Sho Tabata; Ryuji Ikeda; Masatatsu Yamamoto; Shunji Shimaoka; Naofumi Mukaida; Yasuo Takeda; Katsushi Yamada; Tomoyoshi Soga; Tatsuhiko Furukawa; Shin-ichi Akiyama
Journal:  Oncotarget       Date:  2014-11-15

9.  Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1.

Authors:  Magdalena Tertil; Klaudia Skrzypek; Urszula Florczyk; Kazimierz Weglarczyk; Halina Was; Guillaume Collet; Alan Guichard; Tomasz Gil; Jaroslaw Kuzdzal; Alicja Jozkowicz; Claudine Kieda; Chantal Pichon; Jozef Dulak
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

10.  Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells.

Authors:  Sho Tabata; Masatatsu Yamamoto; Hisatsugu Goto; Akiyoshi Hirayama; Maki Ohishi; Takuya Kuramoto; Atsushi Mitsuhashi; Ryuji Ikeda; Misako Haraguchi; Kohichi Kawahara; Yoshinari Shinsato; Kentaro Minami; Atsuro Saijo; Yuko Toyoda; Masaki Hanibuchi; Yasuhiko Nishioka; Saburo Sone; Hiroyasu Esumi; Masaru Tomita; Tomoyoshi Soga; Tatsuhiko Furukawa; Shin-Ichi Akiyama
Journal:  Sci Rep       Date:  2018-04-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.